Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
44
Recruiting, industry sponsors, Ophthalmology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed464
44 trials
Showing 1 to 25, recently updated first.
- A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).Pivotal-lookingRecruiting
4D Molecular TherapeuticsIndustry
NCT07867080 · 514 participants (planned) · Start Sep 18, 2026 · Primary completion Jan 2029
Drug: 4D-150 IVT (3x10^10 vg); EYELEA ® (aflibercept) Injection 2 mg (0.05mL) · For: Diabetic Macular Edema (DME)
Sites: Scottsdale, Arizona; Encino, California; Fullerton, California · 95 sites in all
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07496567 · 960 participants (planned) · Start Apr 15, 2026 · Primary completion Jul 31, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Encino, California · 121 sites in all
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07440225 · 960 participants (planned) · Start Mar 27, 2026 · Primary completion Jun 30, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Springdale, Arkansas · 148 sites in all
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07705555 · 960 participants (planned) · Start Aug 27, 2026 · Primary completion Oct 31, 2028
Drug: MK-8748; Aflibercept · For: Diabetic Retinopathy; Macular Edema
Sites: Gilbert, Arizona; Glendale, California; Sacramento, California · 45 sites in all
- A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07614776 · 304 participants (planned) · Start May 27, 2026 · Primary completion Jul 31, 2027
Drug: ABP 938 8 mg; Aflibercept (US) 8 mg · For: Neovascular Age-related Macular Degeneration; nAMD
Sites: Fullerton, California; Long Beach, California; Modesto, California · 101 sites in all
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07705607 · 1,104 participants (planned) · Start Sep 25, 2026 · Primary completion Nov 30, 2028
Drug: MK-8748; Aflibercept · For: Diabetic Retinopathy; Macular Edema
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 31 sites in all
- A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher SyndromePivotal-lookingRecruiting
Nacuity Pharmaceuticals, Inc.Industry
NCT07710196 · 80 participants (planned) · Start Oct 23, 2026 · Primary completion Apr 2029
Drug: Placebo; NPI-001 · For: Retinitis Pigmentosa (RP); Usher Syndrome
Sites: Dallas, Texas
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07621809 · 570 participants (planned) · Start Jul 16, 2026 · Primary completion Aug 15, 2029
Drug: VAY736; Placebo · For: Sjögren´s Disease
Sites: Peoria, Arizona; Searcy, Arkansas; Van Nuys, California · 72 sites in all
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMDPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06847542 · 250 participants (planned) · Start Nov 27, 2025 · Primary completion Nov 15, 2028
Drug: Ranibizumab · For: Neovascular Age-related Macular Degeneration
Sites: Innsbruck, Austria; Linz, Austria; Mistelbach, Austria · 64 sites in all
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06541704 · 975 participants (planned) · Start Oct 30, 2024 · Primary completion Jul 31, 2028
Drug: Pozelimab; Cemdisiran and 1 more · For: Age-related Macular Degeneration (AMD); Geographic Atrophy (GA)
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 233 sites in all
- A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT05767047 · 48 participants (planned) · Start Mar 23, 2023 · Primary completion Mar 17, 2036
Drug: Apremilast · For: Behçet's Disease; Juvenile Psoriatic Arthritis
Sites: Thessaloniki, Greece; Kfar Saba, Israel; Valencia, Spain · 7 sites in all
- A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06635148 · 274 participants (planned) · Start Sep 19, 2024 · Primary completion Aug 24, 2029
Drug: JNJ-81201887 · For: Geographic Atrophy; Macular Degeneration
Sites: Tucson, Arizona; Fullerton, California; La Jolla, California · 104 sites in all
- A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTOPivotal-lookingRecruiting
Kodiak Sciences IncIndustry
NCT07734844 · 910 participants (planned) · Start Aug 3, 2026 · Primary completion Aug 31, 2028
Drug: Tabirafusp tedromer; Aflibercept (2.0 mg) · For: Diabetic Macular Edema (DME)
Sites: Scottsdale, Arizona; Bakersfield, California; Glendale, California · 52 sites in all
AbbVieAbbVie (ABBV)
NCT07007065 · 561 participants (planned) · Start Nov 5, 2025 · Primary completion Mar 2033
Drug: Surabgene Lomparvovec (ABBV-RGX-314); Ranibizumab Control · For: Neovascular Age-related Macular Degeneration
Sites: Mesa, Arizona; Sun City, Arizona; Campbell, California · 138 sites in all
- Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07592273 · 576 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 2028
Drug: Surabgene Lomparvovec; Sham and 2 more · For: Diabetic Retinopathy
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 40 sites in all
- Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)Pivotal-lookingRecruiting
Ray Therapeutics, Inc.Industry
NCT07901751 · 60 participants (planned) · Start Oct 2026 · Primary completion Oct 2028
Drug: RTx-015 · For: Retinitis Pigmentosa (RP); Inherited Retinal Diseases
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 14 sites in all
- Extension Study for the Port Delivery System With Ranibizumab (Portal)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03683251 · 1,000 participants (planned) · Start Sep 20, 2018 · Primary completion Dec 31, 2029
Drug: PDS Implant with Ranibizumab 100 mg/mL · For: Neovascular Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 165 sites in all
- Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseasePivotal-lookingRecruiting
Vor BiopharmaIndustry
NCT07404865 · 250 participants (planned) · Start Feb 26, 2026 · Primary completion Dec 2028
Drug: Telitacicept; Placebo · For: Primary Sjogren's Disease
Sites: Chandler, Arizona; Flagstaff, Arizona; Glendale, Arizona · 49 sites in all
- Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPivotal-lookingRecruiting
4D Molecular TherapeuticsIndustry
NCT07064759 · 480 participants (planned) · Start Jul 22, 2025 · Primary completion Nov 2027
Drug: 4D-150 IVT (3E10 vg/eye); EYLEA® (aflibercept) Injection 2 mg (0.05mL) · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Scottsdale, Arizona; Sun City, Arizona; Tucson, Arizona · 126 sites in all
- Phase III Study of OT202 in Treating Moderate to Severe Dry EyePivotal-lookingRecruiting
Ocumension Therapeutics (Suzhou) Co., LtdIndustry
NCT07740564 · 842 participants (planned) · Start Aug 25, 2026 · Primary completion Jan 2029
Drug: OT202 conc 1%; Placebo · For: Dry Eye
Sites: Bengbu, China; Hefei, China; Beijing, China · 49 sites in all
- A Study to Compare GNR-139 and Eylea® in Patients With nAMDPivotal-lookingRecruiting
AO GENERIUMIndustry
NCT07844148 · 180 participants (planned) · Start Jul 22, 2026 · Primary completion May 2028
Drug: aflibercept; Eylea · For: nAMD
Sites: Cheboksary, Russia; Chelyabinsk, Russia; Yekaterinburg, Russia · 14 sites in all
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)Pivotal-lookingRecruiting
Adverum Biotechnologies, Inc.Industry
NCT07482176 · 534 participants (planned) · Start Mar 16, 2026 · Primary completion Nov 15, 2027
Drug: Aflibercept · For: Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 79 sites in all
- A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionPivotal-lookingRecruiting
YS Life Science Co., Ltd.Industry
NCT07661329 · 600 participants (planned) · Start Jun 2, 2026 · Primary completion Nov 1, 2027
Drug: Bimatoprost ophthalmic solution 0.01% YSBP; bimatoprost ophthalmic solution 0.01% (Lumigan®) · For: Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OH)
Sites: Beverly Hills, California; Inglewood, California; Newport Beach, California · 22 sites in all
- Study of ALK-001 on the Progression of Stargardt DiseasePivotal-lookingRecruiting
Alkeus Pharmaceuticals, Inc.Industry
NCT07419334 · 230 participants (planned) · Start Jun 3, 2026 · Primary completion Oct 2029
Drug: ALK-001; Placebo · For: Stargardt Disease
Sites: Phoenix, Arizona; Aurora, Colorado; Gainesville, Florida · 14 sites in all
- Study of 5% VVN001 Ophthalmic Solution in Dry Eye DiseasePivotal-lookingRecruiting
VivaVision Biotech, IncIndustry
NCT06360133 · 700 participants (planned) · Start Apr 1, 2024 · Primary completion Apr 30, 2027
Drug: VVN001 Ophthalmic Solution, 5%; VVN001 Ophthalmic Solution, Vehicle · For: Dry Eye
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.